ArticleJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology2021
Silver nanoparticles-chitosan composites activity against resistant bacteria: tolerance and biofilm inhibition.
Article in Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Silver nanoparticles in biomedicine: green synthesis, precision theranostics, and future clinical translation.Folia microbiologica · 2026Review
- Radiolytic Synthesis of Chitosan-Stabilized Silver Nanoparticles via Electron Beam Irradiation for Enhanced Antibacterial Activity AgainstInternational journal of molecular sciences · 2026Article
- Bacterial Cellulose Hydrogel Incorporating Silver Nanoparticles: A Nanobiotechnological Approach for Skin Infections Caused by MRSA and MRSE.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Green Synthesized Silver Nanoparticles from Meyna Laxiflora: Binding with HSA and Anti-biofilm Potential.Cell biochemistry and biophysics · 2026Article
- Investigating silver- and gold-functionalized electrospun PHBV fibers as dual-action antimicrobial and immunomodulatory biomaterials.Frontiers in bioengineering and biotechnology · 2026Article
- Mechanistic insights and therapeutic innovations in engineered nanomaterial-driven disruption of biofilm dynamics.RSC advances · 2025Review
- Development and Perfection of Marine-Based Insecticide Biofilm for Pea Seed Protection: Experimental and Computational Approaches.Molecules (Basel, Switzerland) · 2025Article
- Reducing the effective dose of doxycycline using chitosan silver nanocomposite as a carriers on gram positive and gram-negative bacteria.Scientific reports · 2024Article
- Ocimum basilicum seed-mediated green synthesis of silver nanoparticles: characterization and evaluation of biological properties.Discover nano · 2024Article
- Synthesis and Application of Silver Nanoparticles for Caries Management: A Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mechanisms of Triton X-100 reducing the AgWorld journal of microbiology & biotechnology · 2024Article
- Antibacterial and Antibiofilm Potential of Bacterial Cellulose Hydrogel Containing Vancomycin against Multidrug-ResistantBiology · 2024Article
- Advancing biomedical applications: an in-depth analysis of silver nanoparticles in antimicrobial, anticancer, and wound healing roles.Frontiers in pharmacology · 2024Review
- Antibiofilm Effects of Oleuropein againstFoods (Basel, Switzerland) · 2023Article
- Saponin-Derived Silver Nanoparticles fromAntibiotics (Basel, Switzerland) · 2023Article
- Advanced Hydrogels Combined with Silver and Gold Nanoparticles against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effectiveness of silver nanoparticles-chitosan composites (AgNPs) with different morphologies and particle size distributions against resistant bacteria and biofilm formation. Four different samples were prepared by a two-step procedure using sodium borohydride and ascorbic acid as reducing agents and characterized by UV-Vis absorption spectra, scanning transmission electron microscopy. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the AgNPs were determined according to the Clinical and Laboratory Standards Institute (CLSI) against clinical isolates multidrug-resistant and strains of the American Type Culture Collection (ATCC). An assay was performed to determine the MICs during 20 successive bacteria exposures to AgNPs to investigate whether AgNPs induce tolerance in bacteria. The antibiofilm activities of AgNPs were also evaluated by determining the minimum biofilm inhibitory concentration (MBIC). The spherical AgNPs present diameters ranging from 9.3 to 62.4 nm, and some samples also have rod-, oval-, and triangle-shaped nanoparticles. The MIC and MBC values ranged from 0.8 to 25 μg/mL and 3.1 to 50 μg/mL, respectively. Smaller and spherical AgNPs exhibited the highest activity, but all the AgNPs developed in this study exhibit bactericidal activity. There was no significant MIC increase after 20 passages to the AgNPs. Regarding the antibiofilm activity, MBICs ranged from 12.5 to 50 μg/mL. Again, smaller and spherical nanoparticles presented the best results with phenotypic inhibition of production of slime or exopolysaccharide (EPS) matrix. Thus, it was concluded that AgNPs have a promising potential against resistant bacteria and bacteria that grow on biofilms without inducing tolerance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11051-021-05314-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.